Diagnos Inc
XTSX:ADK
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.19
0.38
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Diagnos Inc
Net Income (Common)
Diagnos Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Diagnos Inc
XTSX:ADK
|
Net Income (Common)
-CA$4.8m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-5%
|
|
|
Biotricity Inc
NASDAQ:BTCY
|
Net Income (Common)
-$5.7m
|
CAGR 3-Years
42%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
C
|
CardioComm Solutions Inc
XTSX:EKG
|
Net Income (Common)
-CA$404.8k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
13%
|
CAGR 10-Years
2%
|
|
|
Avricore Health Inc
XTSX:AVCR
|
Net Income (Common)
-CA$1.6m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
10%
|
CAGR 10-Years
5%
|
|
|
N
|
NetraMark Holdings Inc
CNSX:AIAI
|
Net Income (Common)
-CA$3.3m
|
CAGR 3-Years
13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Diagnos Inc
Glance View
Diagnos, Inc. engages in the provision of healthcare technical services through the use of artificial intelligence (AI). The company is headquartered in Brossard, Quebec. The company went IPO on 2000-09-27. FLAIRE allows for quick modifying and developing of applications, such as CARA (Computer Assisted Retina Analysis). The firm markets CARA, a software platform which assists health specialists in the detection of diabetic retinopathy. CARA is an in-house hosted Web-based application that integrates fundus cameras with an image processing engine over an Internet connection. CARA offers payers and patients in automating the screening process. The CARA suite of applications allows an eye care specialist to clearly visualize both normal retinal landmarks, such as optic nerve, vascular system, macula, fovea, as well as pathological changes (exudates, hemorrhages, micro-aneurisms, neo-vascularization). The firm also offers data mining consulting services in the natural resources sector.
See Also
What is Diagnos Inc's Net Income (Common)?
Net Income (Common)
-4.8m
CAD
Based on the financial report for Sep 30, 2025, Diagnos Inc's Net Income (Common) amounts to -4.8m CAD.
What is Diagnos Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-5%
Over the last year, the Net Income (Common) growth was -42%. The average annual Net Income (Common) growth rates for Diagnos Inc have been -23% over the past three years , -12% over the past five years , and -5% over the past ten years .